Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts

Clinical trials on IgA nephropathy (IgAN) have historically demonstrated a treatment effect on adverse outcomes, such as a 50% decline in the estimated glomerular filtration rate (eGFR) or kidney failure. Thus, trials required long follow-up, were expensive, with limited feasibility. This changed in 2016 when the Kidney Health Initiative analysis of 11 clinical trials demonstrated that a treatment effect on proteinuria over approximately 9 months was a reasonable surrogate for the effect on a hard kidney end point.